Temp


← Back to Cases

FDA v. Wages and White Lion Investments, LLC

Docket: 23-1038 Decision Date: 2025-04-02
View Official PDF
This links to the official slip opinion PDF.
How to read this page

Below are plain-language sections to help you understand what the Court decided in FDA v. Wages and White Lion Investments, LLC and why it matters. Quotes are taken from the syllabus (the Court’s short summary at the start of the opinion).

Summary

A short, plain-English overview of FDA v. Wages and White Lion Investments, LLC.

The Supreme Court reviewed whether the FDA lawfully denied authorization for certain e-cigarette products under the Family Smoking Prevention and Tobacco Control Act. The Fifth Circuit had previously found the FDA's actions arbitrary and capricious, but the Supreme Court vacated this decision, determining the FDA's actions were consistent with its guidance. The case involved issues of scientific evidence requirements, comparative efficacy, and device type considerations in the FDA's decision-making process.

Holding

The single most important “bottom line” of what the Court decided in FDA v. Wages and White Lion Investments, LLC.

The Court held that the FDA's denial of the e-cigarette applications was consistent with its predecisional guidance and not arbitrary or capricious.

Constitutional Concepts

These are the Constitution-related themes that appear in FDA v. Wages and White Lion Investments, LLC. Click a concept to see other cases that involve the same idea.

  • Why Due Process is relevant to FDA v. Wages and White Lion Investments, LLC

    The case involves the FDA's regulatory authority and the standards it applied, which implicates procedural due process concerns under the Administrative Procedure Act.

    Syllabus excerpt (verbatim)
    Respondents petitioned for judicial review of the FDA's denial orders under the Administrative Procedure Act (APA).
  • Why Separation of Powers is relevant to FDA v. Wages and White Lion Investments, LLC

    The case involves the FDA's exercise of regulatory power, which touches on the separation of powers between the legislative authority that enacted the TCA and the executive authority of the FDA.

    Syllabus excerpt (verbatim)
    The TCA requires the FDA to deny such an application unless an applicant shows that its product 'would be appropriate for the protection of the public health.'

Key Quotes

Short excerpts from the syllabus in FDA v. Wages and White Lion Investments, LLC that support the summary and concepts above.

  • The FDA's denial orders were sufficiently consistent with its predecisional guidance.
  • The FDA rejected respondents' applications because that test was not met.
  • The Fifth Circuit read Calcutt too broadly.

Leave a Reply

Your email address will not be published. Required fields are marked *